{"id":45337,"date":"2022-06-22T08:01:29","date_gmt":"2022-06-22T06:01:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/"},"modified":"2022-06-22T08:01:29","modified_gmt":"2022-06-22T06:01:29","slug":"poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/","title":{"rendered":"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Shareholders approved all proposed resolutions<\/b>\n<\/li>\n<\/ul>\n<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxel.com%2F&amp;esheet=52757664&amp;newsitemid=20220621006105&amp;lan=en-US&amp;anchor=POXEL+SA&amp;index=1&amp;md5=6a31163901a50e1fb5aaebc818126360\" rel=\"nofollow noopener\" shape=\"rect\">POXEL SA<\/a> (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The meeting was held at Coll\u00e8ge H\u00f4tel, 5 Place Saint-Paul, 69005 LYON, and was chaired by Pierre Legault, Chairman of the Board of Directors.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220621006105\/en\/729413\/4\/Logo_Without_Background.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220621006105\/en\/729413\/21\/Logo_Without_Background.jpg\"><\/a><\/p>\n<p>\nWith a quorum of 40.787 %, the shareholders approved all the resolutions that were recommended by the Board of Directors, including the financial statements for the 2021 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the Directors, as well as delegations related to financial transactions granted to the Board of Directors.\n<\/p>\n<p>\nShareholders also approved the renewal of Pierre Legault and Janice Bourque as Board members.\n<\/p>\n<p>\nDetails on the voting results, as well as the presentation that was made during the meeting, will be available later today on the company\u2019s website, in the Investors \/ Shareholder Info \/ Annual General Meeting Documents section.\n<\/p>\n<p>\n<b>About Poxel SA<\/b>\n<\/p>\n<p>\nPoxel is a <b>clinical stage biopharmaceutical company<\/b> developing <b>innovative treatments for chronic serious diseases with metabolic pathophysiology<\/b>, including <b>non-alcoholic steatohepatitis (NASH)<\/b> and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, <b>PXL065<\/b> (deuterium-stabilized <i>R<\/i>-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). <b>PXL770<\/b>, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives<i>. <\/i>For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). <b>TWYMEEG<sup>\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan<i>.<\/i> Poxel expects to receive royalties and sales-based payments from Sumitomo Pharma. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.\n<\/p>\n<p>\nFor more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=52757664&amp;newsitemid=20220621006105&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=2&amp;md5=c0787fc8201bcfb7dede0cd7feeb837b\" rel=\"nofollow noopener\" shape=\"rect\">www.poxelpharma.com<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor relations \/ Media<\/b>\n<\/p>\n<p>\nAur\u00e9lie Bozza<br \/>\n<br \/>Investor Relations &amp; Communication Senior Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x61;&#117;re&#x6c;&#x69;&#101;&#46;b&#x6f;&#x7a;&#x7a;&#97;&#64;p&#x6f;&#x78;&#101;&#108;p&#x68;&#x61;&#x72;&#109;a&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x61;&#x75;&#x72;&#x65;&#x6c;&#105;&#101;&#46;&#98;ozz&#x61;&#x40;&#x70;&#x6f;&#x78;&#x65;&#108;&#112;&#104;arm&#x61;&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>+33 6 99 81 08 36\n<\/p>\n<p>\nElizabeth Woo<br \/>\n<br \/>Senior Vice President, Investor Relations &amp; Communication<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;e&#108;&#x69;&#x7a;a&#98;&#x65;&#x74;h&#46;&#x77;&#x6f;o&#64;&#x70;&#x6f;x&#101;&#x6c;p&#104;&#97;&#x72;m&#97;&#x2e;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x65;l&#x69;&#122;&#x61;&#98;e&#x74;h&#x2e;&#119;&#x6f;&#111;&#64;&#x70;&#111;&#x78;&#101;l&#x70;h&#x61;&#114;&#x6d;&#97;&#46;&#x63;o&#x6d;<\/a>\n<\/p>\n<p>\nNewCap<br \/>\n<br \/>Emmanuel Huynh or Arthur Rouill\u00e9<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#111;:&#x70;o&#x78;&#101;&#x6c;&#64;n&#x65;&#119;&#x63;&#97;p&#x2e;e&#x75;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x6f;x&#x65;&#x6c;&#64;&#x6e;e&#x77;&#x63;&#97;&#x70;&#46;&#x65;&#x75;<\/a><br \/>+33 1 44 71 94 94\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shareholders approved all proposed resolutions LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45337","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Shareholders approved all proposed resolutions LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-22T06:01:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220621006105\/en\/729413\/21\/Logo_Without_Background.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting\",\"datePublished\":\"2022-06-22T06:01:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/\"},\"wordCount\":446,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621006105\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/\",\"name\":\"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621006105\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"datePublished\":\"2022-06-22T06:01:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621006105\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621006105\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting - Pharma Trend","og_description":"Shareholders approved all proposed resolutions LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-22T06:01:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220621006105\/en\/729413\/21\/Logo_Without_Background.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting","datePublished":"2022-06-22T06:01:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/"},"wordCount":446,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220621006105\/en\/729413\/21\/Logo_Without_Background.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/","url":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/","name":"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220621006105\/en\/729413\/21\/Logo_Without_Background.jpg","datePublished":"2022-06-22T06:01:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220621006105\/en\/729413\/21\/Logo_Without_Background.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220621006105\/en\/729413\/21\/Logo_Without_Background.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-results-from-june-21-2022-ordinary-annual-and-extraordinary-general-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45337"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45337\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}